PMID- 35950215
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220813
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 29
DP  - 2022 Sep 13
TI  - NAIRscore as a biomarker for the quality of immune response to neoantigens is 
      related with an increased overall survival in multiple myeloma.
PG  - 285-295
LID - 10.1016/j.omtn.2022.07.006 [doi]
AB  - Neoantigen provides a promising breakthrough in tumor immunotherapy, although 
      only a subset of patients responds well due to the quality of their immune 
      response. However, few biomarkers have been reported to measure the quality of 
      immune response to neoantigens and to predict prognosis of patients with multiple 
      myeloma (MM). Here, we first developed a neoantigen-prediction pipeline starting 
      from outcomes of somatic mutations and gene-expression profiles. Given the 
      expression of some specific marker genes, the human leukocyte antigen (HLA)-I 
      score and the cytolytic score were evaluated respectively to reflect HLA-I 
      molecular expression and CD8+ T/natural killer (NK) cell abundance. According to 
      the process of the immune response to neoantigens, we comprehensively took 
      neoantigen load, cytolytic score, and HLA-I score to construct a neoantigen 
      immune response score (NAIRscore), in which the HLA-I score presented a hazard 
      ratio (HR) of less than 1, while the cytolytic score and neoantigen load 
      presented a HR of greater than 1. Meanwhile, NAIRscore presented a competitive 
      advantage to stratify MM samples. Especially, those exhibiting high NAIRscore 
      correlated with an increased overall survival (OS), echoing the underlying 
      molecular signatures of lower driver-gene mutations and down-regulated immune 
      response. Notably, an online tool based on this study is provided to identify 
      neoantigens and predict OS.
CI  - (c) 2022 The Authors.
FAU - Jian, Xingxing
AU  - Jian X
AD  - Bioinformatics Center & National Clinical Research Centre for Geriatric Disorders 
      & Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China.
FAU - Xu, Linfeng
AU  - Xu L
AD  - Shanghai-MOST Key Laboratory of Health and Disease Genomics, Institute for Genome 
      and Bioinformatics, Shanghai Institute for Biomedical and Pharmaceutical 
      Technologies, Shanghai, China.
AD  - School of Medical Instrument and Food Engineering, University of Shanghai for 
      Science and Technology, Shanghai, China.
FAU - Zhao, Jingjing
AU  - Zhao J
AD  - Shanghai-MOST Key Laboratory of Health and Disease Genomics, Institute for Genome 
      and Bioinformatics, Shanghai Institute for Biomedical and Pharmaceutical 
      Technologies, Shanghai, China.
AD  - College of Food Science and Technology, Shanghai Ocean University, Shanghai, 
      China.
FAU - Wang, Yanhui
AU  - Wang Y
AD  - College of Food Science and Technology, Shanghai Ocean University, Shanghai, 
      China.
FAU - Zhou, Wen
AU  - Zhou W
AD  - Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key 
      Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of 
      Education, Cancer Research Institute, School of Basic Medical Sciences, Central 
      South University, Changsha, Hunan, China.
FAU - Xie, Lu
AU  - Xie L
AD  - Bioinformatics Center & National Clinical Research Centre for Geriatric Disorders 
      & Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, 
      Hunan, China.
AD  - Shanghai-MOST Key Laboratory of Health and Disease Genomics, Institute for Genome 
      and Bioinformatics, Shanghai Institute for Biomedical and Pharmaceutical 
      Technologies, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220712
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC9352810
OTO - NOTNLM
OT  - NAIRscore
OT  - multiple myeloma
OT  - neoantigen
OT  - neoantigen immune response score
OT  - neoantigen prediction pipeline
OT  - overall-survival prediction
OT  - quality of immune response to neoantigens
COIS- The authors declare no competing interests.
EDAT- 2022/08/12 06:00
MHDA- 2022/08/12 06:01
PMCR- 2022/07/12
CRDT- 2022/08/11 02:26
PHST- 2022/02/15 00:00 [received]
PHST- 2022/07/08 00:00 [accepted]
PHST- 2022/08/11 02:26 [entrez]
PHST- 2022/08/12 06:00 [pubmed]
PHST- 2022/08/12 06:01 [medline]
PHST- 2022/07/12 00:00 [pmc-release]
AID - S2162-2531(22)00175-5 [pii]
AID - 10.1016/j.omtn.2022.07.006 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2022 Jul 12;29:285-295. doi: 10.1016/j.omtn.2022.07.006. 
      eCollection 2022 Sep 13.